US Stock MarketDetailed Quotes

AXGN AxoGen

Watchlist
  • 19.460
  • -0.650-3.23%
Close Feb 26 16:00 ET
  • 17.120
  • -2.340-12.02%
Pre 04:01 ET
862.93MMarket Cap-84.61P/E (TTM)

About AxoGen Company

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm’s products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Company Profile

SymbolAXGN
Company NameAxoGen
Listing DateAug 9, 2013
Founded1977
CEOMr. Michael D. Dale
MarketNASDAQ
Employees428
Fiscal Year Ends12-31
Address13631 Progress Boulevard,Suite 400
CityAlachua
ProvinceFlorida
CountryUnited States of America
Zip Code32615
Phone1-386-462-6800

Company Executives

  • Name
  • Position
  • Salary
  • Michael D. Dale
  • Director, Chief Executive Officer and President
  • --
  • Nir Naor
  • Chief Financial Officer and Principal Accounting Officer
  • 60.29K
  • Todd Puckett
  • Vice President, Manufacturing
  • --
  • Erick Wayne DeVinney
  • Vice President, Peripheral Nerve Science
  • 1.51M
  • Paul G. Thomas
  • Chairman of the Board
  • 220.00K
  • Kathy Johnson Weiler
  • Independent Director
  • 293.37K
  • Alan M. Levine
  • Independent Director
  • 217.50K
  • William P. Burke
  • Independent Director
  • 220.00K
  • Amy A. Wendell
  • Lead Independent Director
  • 255.00K
  • Guido J. Neels
  • Independent Director
  • 217.50K
  • Dr. Joseph Adrian Tyndall, M.D.,M.P.H.
  • Independent Director
  • 205.00K
  • John H. Johnson
  • Independent Director
  • 215.00K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
Unlock Now
Discussing
Tesla's earnings caused fluctuations, what's your market outlook?
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More